CTOs on the Move

Northern Light Health

www.northernlighthealth.org

 
Northern Light Health exists to make healthcare work for you. That is our mission. That is our purpose. Northern Light Health is the most expansive integrated health care system in Maine. We provide care to people from Portland to Presque Isle and from Blue Hill to Greenville. We are comprised of nine member hospitals with 584 long-term beds, a single physician-led medical group, eight nursing homes, five emergency transport members, 37 primary care locations, and we employ more than 12,000 people in Maine.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Michael Corbett
Associate Vice President, IS Infrastructure and Operations Profile
April Giard
Vice President and Chief Information Officer Profile

Similar Companies

Lakeridge Health

Lakeridge Health is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Lakeridge Health is based in Oshawa, ON. You can find more information on Lakeridge Health at www.lakeridgehealth.on.ca

Senior Concepts

Senior Concepts, Inc. is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fuchs Ems and Medical Transport Services

Fuchs Ems and Medical Transport Services is a Fair Lawn, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.

Capital District Physicians` Health Plan

Founded in 1984 as a physician-founded and guided health plan, CDPHP and its affiliates currently serve members in 24 counties throughout New York with a full family of products.